BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 17, 2009
View Archived Issues
InterMune Prices Public Offering on Heels of Phase III IPF Data
A week after Phase III pirfenidone data in idiopathic pulmonary fibrosis sent its stock up 36 percent, InterMune Inc. decided to sell 3.5 million shares in a public offering. (BioWorld Today)
Read More
Geron Seeking $50M Plus to Support More Trials
Read More
New Tissue Engineering Path: Micro-tissues Formed in '3-D'
Read More
Stimulus Bill Allots $10B for Biomedical Research
Read More
Holiday Notice
Read More
Corrections & Clarifications
Read More
Clinic Roundup
Read More
Earnings Roundup
Read More
Other News To Note
Read More
Restructuring Roundup
Read More
